Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest oxycodone/ibuprofen

Executive Summary

Proposed brand name for Forest's oxycodone/ibuprofen fixed-dosed combination is Combunox. Forest will submit an additional clinical study in March to meet the recommendations set by FDA in a 2002 "approvable" letter (1"The Pink Sheet" Oct. 18, 2002, In Brief)...

You may also be interested in...



Forest pain combo “approvable”

Forest Labs' oxycodone/ibuprofen combination must undergo additional safety and efficacy testing, FDA says in deeming the pain product "approvable." Forest had expected approval by year-end (1"The Pink Sheet" Oct. 21, p. 23)...

Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.

Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel